title: Decreased prevalence of virulence factors among ciprofloxacin-resistant uropathogenic Escherichia coli isolates.
abstract: Ciprofloxacin resistance was identified in 18% and 6% of consecutively collected, clinically significant urinary tract isolates of Escherichia coli from inpatients and outpatients, respectively. In comparison to ciprofloxacin-susceptible isolates, there were fewer resistant isolates that expressed beta-hemolysis (outpatient, 9% versus 87%, P < 0.0001; inpatient, 4% versus 76%, P < 0.0001) and that had a papEF genotype, genes encoding P fimbriae (outpatient, 30% versus 70%, P = 0.0004; inpatient, 26% versus 70%, P < 0.0001).
authors.affiliation: Toronto Medical Laboratories and Mount Sinai Hospital, Toronto, Ontario, Canada, M5G 1X5.
authors.forename: S J
authors.initials: SJ
authors.lastname: Drews
authors.forename: S M
authors.initials: SM
authors.lastname: Poutanen
authors.forename: T
authors.initials: T
authors.lastname: Mazzulli
authors.forename: A J
authors.initials: AJ
authors.lastname: McGeer
authors.forename: A
authors.initials: A
authors.lastname: Sarabia
authors.forename: S
authors.initials: S
authors.lastname: Pong-Porter
authors.forename: Y
authors.initials: Y
authors.lastname: Rzayev
authors.forename: B
authors.initials: B
authors.lastname: Willey
authors.forename: K
authors.initials: K
authors.lastname: Green
authors.forename: D E
authors.initials: DE
authors.lastname: Low
mesh_terms: D001437:Bacteriuria / Q000382:microbiology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000472:pathogenicity*; D006461:Hemolysis; D006801:Humans; D009268:Nalidixic Acid / Q000494:pharmacology; D037521:Virulence Factors / Q000032:analysis*
chemical_list: D037521:Virulence Factors; D009268:Nalidixic Acid; D002939:Ciprofloxacin